- Home
- BRIA vs HOWL Comparison
BRIA vs HOWL Comparison
Compare BRIA & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRIA
- HOWL
- Stock Information
- Founded
- BRIA 2011
- HOWL 2017
- Country
- BRIA Singapore
- HOWL United States
- Employees
- BRIA N/A
- HOWL N/A
- Industry
- BRIA
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- BRIA
- HOWL Health Care
- Exchange
- BRIA NYSE
- HOWL Nasdaq
- Market Cap
- BRIA 62.0M
- HOWL 53.4M
- IPO Year
- BRIA 2024
- HOWL 2021
- Fundamental
- Price
- BRIA $2.38
- HOWL $1.25
- Analyst Decision
- BRIA
- HOWL Strong Buy
- Analyst Count
- BRIA 0
- HOWL 3
- Target Price
- BRIA N/A
- HOWL $8.33
- AVG Volume (30 Days)
- BRIA 2.8K
- HOWL 549.7K
- Earning Date
- BRIA 08-15-2025
- HOWL 08-07-2025
- Dividend Yield
- BRIA N/A
- HOWL N/A
- EPS Growth
- BRIA N/A
- HOWL N/A
- EPS
- BRIA 92.24
- HOWL N/A
- Revenue
- BRIA $59,695,825.00
- HOWL $1,143,000.00
- Revenue This Year
- BRIA N/A
- HOWL N/A
- Revenue Next Year
- BRIA N/A
- HOWL N/A
- P/E Ratio
- BRIA $0.03
- HOWL N/A
- Revenue Growth
- BRIA 8.03
- HOWL N/A
- 52 Week Low
- BRIA $1.78
- HOWL $0.60
- 52 Week High
- BRIA $4.38
- HOWL $4.18
- Technical
- Relative Strength Index (RSI)
- BRIA N/A
- HOWL 45.36
- Support Level
- BRIA N/A
- HOWL $1.03
- Resistance Level
- BRIA N/A
- HOWL $1.10
- Average True Range (ATR)
- BRIA 0.00
- HOWL 0.07
- MACD
- BRIA 0.00
- HOWL -0.02
- Stochastic Oscillator
- BRIA 0.00
- HOWL 22.81
About BRIA BRILLIA INC
BrilliA Inc is engaged in business of sales and marketing of lingerie's products including bra, panty and body suit, mainly serving the American, European and other markets.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.